The Lancet HIV

The Lancet HIV will build on The Lancet’s rich history of publishing HIV/AIDS research to provide a reliable foundation for advocacy and for programmatic and political change. The journal will publish the best translational, epidemiological, clinical, and implementation research. Most importantly, the journal will aim to unify these disciplines across a single vision for the health of those living with HIV. The Lancet HIV has been founded on two clear principles. First, the task of defecting HIV has not been accomplished and the journal will work in partnership with others to accelerate our response immediately. Second, The Lancet HIV is a new journal intending to reposition HIV/AIDS for a new era of sustainable development. We invite you to join us in this two-fold mission.

Editor in Chief: Peter Hayward
The Lancet HIV
Global Print Circulation
Avg. Global eTOC Distribution
Circulation updated on November 9, 2022. Circulation maintained at 5,000 from controlled subscribers and/or the inclusion of sponsored distribution. For additional information please contact your Elsevier Sales Representative eTOC Metrics: 6 Month Average of eTOC sends - Nov 2022 to April 2023


Display Advertising

Recruitment Advertising

Looking for more information?

If you would like to be contacted by one of our advertising experts, please complete our Request Contact form and we will get right back to you.